Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


National Glaucoma Research
Completed Award

Dr. Peter P. De Deyn

Peter P. De Deyn, M.D., Ph.D.

Institute Born-Bunge
Antwerp, Belgium

Title: Cerebrospinal Fluid Pressure At The Link Between Glaucoma And Alzheimer's Disease
Non-Technical Title: Searching The Link Between Alzheimer's Disease And Increased Risk Of Glaucoma

Debby Van Dam, M.Sc., Ph.D.
Institute Born-Bunge

Duration: July 1, 2012 - June 30, 2014
Award Type: Standard
Award Amount: $100,000


Alzheimer's disease patients may be at a high risk of developing glaucoma. Drs. De Deyn, Van Dam, and colleagues are studying the underlying disease mechanisms responsible for this higher risk, both in patients and in mice engineered to have Alzheimer's disease (AD). These investigators hypothesize that reduced pressure in the liquid that surrounds the brain and spine, called cerebrospinal fluid, may be a major factor in this process.


Drs. De Deyn, Van Dam, and colleagues will study the disease mechanisms underlying the link between Alzheimer's disease and increased risk of glaucoma, both in patients and in a mouse model. They propose that reduced cerebrospinal fluid (CSF) pressure and a high eye pressure (called a trans-lamina cribrosa pressure gradient) in the eye play an important role in the development of glaucoma in Alzheimer's disease patients.

These researchers will also evaluate whether brain shrinkage, typical for Alzheimer's disease, could be the cause of the reduced CSF pressure. In parallel, they will determine whether mice engineered to have Alzheimer's disease also have glaucoma, and, if so, will determine the underlying disease mechanisms.

This is the first clinical study set up to look at the link between Alzheimer's disease and glaucoma. The study of animals with Alzheimer's disease gives the opportunity to more easily study disease mechanisms at various stages of the disease.

If confirmed, these hypotheses could have remarkable implications in clinical practice. Careful attention by the clinician should be given to the potential for glaucoma in AD patients. Moreover, measurement of CSF pressure could be a monitoring tool in AD patients. Further research could raise some interesting possibilities for therapy. A randomized clinical trial could be recommended to test whether one could prevent the development of glaucoma in AD by manipulating CSF pressure. The use of a valid mouse model for AD would also allow for focused translational research and further insight into underlying pathophysiological mechanisms.


Wostyn P, De Groot V, Van Dam D, Audenaert K, De Deyn PP (2013) Senescent Changes in Cerebrospinal Fluid Circulatory Physiology and Their Role in the Pathogenesis of Normal-tension Glaucoma. Am J Ophthalmol. 2013 156(1):5-14. PubMed Icon Google Scholar Icon

Investigator Biography:

Prof. Dr. Peter Paul De Deyn is a neuropsychiatrist specializing in preclinical and clinical studies of neurodegenerative disease, including Alzheimer's disease and related disorders. He has authored or co-authored more than 500 peer-reviewed papers and edited a series of academic volumes in these fields. He is editor-in-chief of Clinical Neurology and Neurosurgery. He has headed the Laboratory of Neurochemistry and Behaviour at the Institute Born-Bunge, University of Antwerp, Belgium since 1989. Since 2005, he has also been the scientific director of this multidisciplinary research institute, which focuses on better integrating and correlating fundamental, clinical, and neuropathological data concerning neurological conditions, employing molecular genetics, biochemistry, experimental analyses of behavioural alterations, and computational neurosciences. In 2011, he also became Scientific Director of the Alzheimer Research Center in Groningen, The Netherlands.